

DAFTAR PUSTAKA

- Aman, M.A., Soewondo, P., Soelistijo, A.S., Arsana, P.M., Wismandari., Zufry H., Rulli, R. (2019). *Panduan Pengelolaan Dislipidemia di Indonesia*. Penerbit: PB PERKENI. Hal. 5.
- Anwar, B. (2004). Dislipidemia Sebagai Faktor Resiko Penyakit Jantung Koroner. *Jurnal Kesehatan*. Sumatera Utara.
- Arsana, P.M., Rulli, R., Asman, M., AAG, B., Hikmat, P. (2015). *Panduan Pengelolaan Dislipidemia di Indonesia*. Penerbit: PB PERKENI. Hal. 30-32.
- Barkate, H., Patel, P., Shah, D & Vyas, F. (2018). Comparison of Efficacy and Safety of Fixed Dose Combination of Rosuvastatin and Choline Fenofibrate to Fixed Dose Combination of Rosuvastatin and Fenofibrate in Patients of Mixed Dyslipidemia: A Randomized, Open-label, Multicentre Clinical Trial in Indian Population. *Indian Journal of Endocrinology and Metabolism*. 22(5), 627-631.
- Davidson, M.H., Rooney, M.W., Drucker, J., Griffin, H.E., Oosman, S & Beckert, M. (2009). Efficacy and Tolerability of Atorvastatin/Fenofibrate Fixed-Dose Combination Tablet Compared With Atorvastatin and Fenofibrate Monotherapies in Patients With Dyslipidemia: A 12-Week, Multicenter, Double-Blind, Randomized, Parallel-Group Study. *Clinical Therapeutics*. 31(12), 2824-2838.
- DiPiro J.T., Wells B.G., Schwinghammer T.L. and DiPiro C. V., (2015). *Pharmacotherapy Handbook*, Ninth Edit., McGraw-Hill Education Companies, Inggris.
- Dorland WA, Newman. (2010). *Kamus Kedokteran Dorland edisi 31*. Jakarta: Penerbit Buku Kedokteran EGC. p. 702, 1003.
- Erwinanto, Anwar, S., Nugroho, E.P., Pradana, T., Rurus, S., Sodiqur, R., Sutono, K. (2013). *Pedoman Tatalaksana Dislipidemia edisi ke-1*. Penerbit: Centra Communication. Hal. 27-28.
- Ferdinand, K.C., Davidson, M.H., Kelly, M.T & Setze, C.M. (2012). One-Year Efficacy and Safety of Rosuvastatin + Fenofibric Acid Combination Therapy in Patients with Mixed Dyslipidemia. *American Journal of Cardiovascular Drugs*. 12(2), 117-125.
- Feryadi, R. S. (2014). Hubungan Kadar Profil Lipid dengan Kejadian Hipertensi pada Masyarakat Etnik Minangkabau di Kota Padang Tahun 2012. *Jurnal Kesehatan Andalas*. 3(2).

- Goldberg, A.C., Bays, H.E., Ballantyne, C.M., Kelly, M.T., Buttler, S.M., Setze, C.M., et al. (2009). *The American Journal of Cardiology*. 103(4), 515-522.
- Goldberg, A.C., Bittner, V., Pepine, C.J., Kelly, M.T., Thakker, K., Setze, C.M., et al. (2011). Efficacy of Fenofibric Acid Plus Statins on Multiple Lipid Parameters and Its Safety in Women With Mixed Dyslipidemia. *The American Journal of Cardiology*. 107(6), 898-905.
- Harahap, N. (2014). *Penelitian Kepustakaan*. Jurnal Iqra, 8(1), 68-69.
- Harvey, R.A. dan Pamela, C. (2013). *Farmakologi*. Edisi 4. Jakarta: Penerbit buku kedokteran EGC. Hal. 294-303.
- Hasibuan, P., (2018). *Evaluasi Penggunaan Obat Dislipidemia Rawat Jalan di Rumah Sakit Umum Daerah Dr. Pringadi Kota Medan*. Skripsi : Universitas Sumatera Utara.
- Husni, M., Lapau, B & Hardhana, B. (2018). Hubungan Dislipidemia dan Diabetes Mellitus dengan Kejadian Penyakit Jantung Korener Di RSUD. *Caring Nursing Journal*. 2(2) 67-68.
- Inbasekaran, K., Prabu, D., Abu-Yousef, I.A., Majdalawieh, A.F., Pal, S & Gunasekan, C.J. (2016). Comparison of the efficacy and safety of atorvastatin monotherapy and atorvastatin plus fenofibrate combination therapy in combined dyslipidemia. *Journal of Chemical and Pharmaceutical Research*. 8(1), 326-331.
- Jacobson, T.A., Ito, M.K., Maki, K.C., Orringer, C.E., Bays, H.E., Jones, P.H., et al. (2015). National Lipid Association (NLA) recommendation for patient-centered management of dyslipidemia: part 1 (full report). *Journal of Clinical Lipidology*. 9(2) 129-169.
- Jung Rhee, E., Chang Kim, H., Hyeon Kim, J., Young Lee, E., Jin Kim, B., Mi Kim, E., et al. (2019). 2018 Guidelines for the management of dyslipidemia. *The Korean Journal of Internal Medicine*. 34(4), 723-771.
- Jones, P.H., Davidson, M.H., Goldberg, A.C., Pepine, C.J., Kelly, M.T., Buttler, S.M., et al. (2009). *Journal of Clinical Lipidology*. 3(2), 125-137.
- Jones, P.H., Davidson, M.H., Kashyap, M.L., Kelly, M.T., Buttler, S.M., Setze, C.M., et al. (2009). *Atherosclerosis*. 204(1), 208-215.
- Jones, P.H., Cusi, K., Davidson, M.H., Kelly, M.T., Setze, C.M., Thakker, K., et al. (2010). Efficacy and Safety of Fenofibric Acid Co-Administered with Low- or Moderate-Dose Statin in Patients with Mixed Dyslipidemia and Type 2 Diabetes Mellitus. *American Journal of Cardiovascular Drugs*. 10(2), 73-84.

- Kipnes, M.S., Roth, E.M., Rhyne, J.M., Setze, C.M., Lele, A., Kelly, M.T., et al. (2010). Year Two Assessment of Fenofibric Acid and Moderate-Dose Statin Combination A Phase 3, Open-Label, Extension Study. *Clinical Drug Investigation*. 30(1), 51-61.
- Mach, F., Baigent, C., Catapano, A.L., Koskinas, K.C., Casula, M., Badimon, L., et al. (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *European Heart Journal*, 41 (1), 111-188.
- Mahley, R.W. dan Thomas. (2012). *Dasar Farmakologi Terapi Edisi 10*, volume 2. Jakarta. Penerbit Buku Kedokteran. Hal. 943.
- Mahley, R.W. (2014). *Biochemistry and physiology of lipid and lipoprotein metabolism*. Dalam : Backer KL, penyunting. Principles and practice of endocrinology and metabolism. Philadelphia: Lippincott William & Wilkins.
- Marley, J. (2000), Efficacy, effectiveness, efficiency, Australian Prescriber, Vol. 23 (6): 1
- Mohiuddin, S.M., Pepine, C.J., Kelly, M.T., Buttler, S.M., Setze, C.M., Sleep, D.J., et al. (2009). *American Heart Journal*. 157(1), 195-203.
- Murray, Robert K. Daryl K. Granner; Victor W. Rodwell (2009). *Biokimia Harper Ed.27*. Jakarta : EGC: 152-94.
- Murray RK, Granner DK, dan Rodwell VW. (2014). *Biokimia Harper. Edisi 29*. Jakarta: EGC
- Muttaqin, A. (2008). *Buku Ajar Asuhan Keperawatan Klien Dengan Gangguan Sistem Imunologi*. Jakarta: Salemba Medika
- Pengurus Besar Perkeni, (2004). *Definisi, Klasifikasi, Penatalaksanaan, Dislipidemia dalam Petunjuk Praktis Penatalaksanaan Dislipidemia, Departemen Ilmu Penyakit Dalam*. FK - UI, Vol.1.
- Riset Kesehatan Dasar (Riskesdas) (2018). *Badan Penelitian dan Pengembangan Kesehatan Kementerian RI tahun 2018*.
- Romadhon, S., (2018). *Gambaran Dislipidemia Pada Pasien Penyakit Jantung Koroner Di RSUD Ulin Banjarmasin*. Skripsi : Fakultas Kedokteran Universitas Lambung Mangkurat.
- Roth, E.M., Rosenson, R.S., Carlsson, D.M., Fukumoto, S.M., Setze, C.M., Blasetto, J.W., et al. (2010). Efficacy and Safety of Rosuvastatin 5 mg in Combination with Fenofibric Acid 135 mg in Patients with Mixed Dyslipidemia – A Phase 3 Study. *Cardiovascular Drugs and Therapy*. 24(5-6), 421-428.

- Selwyn, A.P. & Braunwald, E. (2005). Ischemic Heart Disease. In: Kasper, D.L., Fauci, A.S., Longo, D.L., Braunwald, E., Hauser, S.L., Jameson, J. L., eds., *Harrison's Principles of Internal Medicine*. 16 th ed. USA: McGraw-Hill 1434-1435.
- Soeharto, I. (2000). Pencegahan dan Penyembuhan Penyakit Jantung. Jakarta: Gramedia Pustaka Utama
- Syafitri. (2019). *Pengaruh Pemberian Ekstrak Seledri(Apiumgraveolens L.) Organik Terhadap Kadar High Density Lipoprotei (HDL) Tikus Putih (Rattusnovergicus) GALUR Sprague Dawley yang Diberi Pakan Tinggi Lemak*. Skripsi : Universitas Bandar Lampung.
- Word Health Organization (WHO). (2018). *Global Health Observatory (GHO) data Available*.
- Zhao, C., Wang, F., Dai, Y., Lin, L., Tong, Q., Liao, Y., et al. (2016). Efficacy and safety of fenofibrate as an add-on in patients with elevated triglyceride despite receiving statin treatment. *International Journal of Cardiology*. 221, 832-836.